PLK4 as a new treatment target for melanoma
Functional and Therapeutic Significance of PLK4 in Melanoma
Researchers are testing whether blocking a protein called PLK4 can slow melanoma growth and point to new treatment options for people with melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11212534 on NIH RePORTER |
What this research studies
This project looks at how the protein PLK4 contributes to melanoma development and how it interacts with common cancer drivers like mutated BRAF. Scientists will use lab-grown melanoma cells, genetic tools such as CRISPR, tumor samples, and animal models to see whether blocking PLK4 stops tumor growth or reduces treatment resistance. The team will map PLK4’s partners and pathways to identify drug combinations that might work when current therapies fail. Findings will be used to guide possible future clinical testing of PLK4-targeting approaches.
Who could benefit from this research
Good fit: People with cutaneous melanoma—especially tumors with BRAF mutations or those that have progressed on standard therapies—would be the most relevant candidates for follow-up clinical trials.
Not a fit: Patients with very early melanomas cured by surgery, non-melanoma skin cancers, or tumors that do not rely on PLK4 are unlikely to receive direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could lead to new targeted drugs or combination therapies for people whose melanoma resists existing treatments.
How similar studies have performed: Preclinical studies in other cancers show PLK4 inhibition can disrupt tumor cell division, but clinical evidence in melanoma is limited and the approach remains largely experimental.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Ahmad, Nihal — University of Wisconsin-Madison
- Study coordinator: Ahmad, Nihal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.